Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Table 1

Anti-VEGF agents in clinical development for ovarian cancer.

Mechanism(s) of action	Drug	Molecular target(s)
VEGF ligand binders	Bevacizumab	VEGF A (all isoforms)
	Aflibercept (VEGF trap)	VEGF A and B, PlGF
VEGF receptor tyrosine kinase inhibitors	Ramucirumab	VEGFR2
	Cediranib	VEGFR1-3, c-Kit, PDGFR-β
	Semaxanib	VEGFR2
Multiple-receptor tyrosine kinase inhibitors	Sunitinib	VEGFR1-3, Flt-3, PDGFR-α, PDGFR-β, c-Kit, CSF-1R, RET
	Sorafenib	VEGFR1-3, PDGFR-β, Flt-3, c-Kit, Raf-1
	Vatalanib	VEGFR1-3, PDGFRβ, c-Kit, c-Fms
	Intedanib (BIBF1120)	VEGFR1-3, PDGFR-α, PDGFR-β, FGFR1-3
	Pazopanib	VEGFR1-2, PDGFR-β, c-Kit
	Motesanib	VEGFR1-3, PDGFR, c-Kit
	Vandetanib	VEGFR2-3, EGFR
	AEE788	VEGFR, EGFR

VEGF: vascular endothelial growth factor, PlGF: placenta growth factor, VEGFR: vascular endothelial growth factor receptor, PDGFR: platelet-derived growth factor receptor, CSF-1R: colony stimulating factor 1 receptor, EGFR: epidermal growth factor receptor.